Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:CDAK NASDAQ:CGEN NASDAQ:OYST NASDAQ:PSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$2.47-0.4%$1.92$1.11▼$5.00$657.37M1.811.57 million shs1.13 million shsCDAKCodiak BioSciences$0.00$0.00$0.05▼$6.98$59K3.711.37 million shsN/ACGENCompugen$1.59-5.9%$1.57$1.13▼$2.66$141.89M2.57365,851 shs329,117 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPSTXPoseida Therapeutics$9.50$9.48$2.32▼$9.67$928.85M1.631.08 million shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics0.00%+4.22%+14.88%+81.62%-37.15%CDAKCodiak BioSciences0.00%0.00%0.00%0.00%0.00%CGENCompugen0.00%-10.67%-4.22%+26.19%-7.56%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PSTXPoseida Therapeutics0.00%0.00%0.00%0.00%+218.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.8693 of 5 stars3.51.00.00.03.33.30.6CDAKCodiak BioSciences0.8266 of 5 stars0.00.00.04.60.61.70.6CGENCompugen1.7828 of 5 stars3.52.00.00.03.30.00.0OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/APSTXPoseida Therapeutics0.415 of 5 stars1.00.00.04.60.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32277.33% UpsideCDAKCodiak BioSciences 0.00N/AN/AN/ACGENCompugen 3.00Buy$4.00151.57% UpsideOYSTOyster Point Pharma 0.00N/AN/AN/APSTXPoseida Therapeutics 2.00Hold$9.50N/ACurrent Analyst Ratings BreakdownLatest CGEN, AUTL, CDAK, PSTX, and OYST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M72.95N/AN/A$1.61 per share1.53CDAKCodiak BioSciences$33.57M0.00N/AN/A$2.39 per share0.00CGENCompugen$27.86M5.09N/AN/A$0.62 per share2.56OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94PSTXPoseida Therapeutics$150.86M6.16N/AN/A$1.08 per share8.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/8/2025 (Estimated)CDAKCodiak BioSciences-$37.16M-$0.69N/A∞N/A-51.13%-109.51%-34.44%N/ACGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/APSTXPoseida Therapeutics-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/ALatest CGEN, AUTL, CDAK, PSTX, and OYST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AUTLAutolus Therapeutics-$0.2329N/AN/AN/A$12.92 millionN/A8/5/2025Q2 2025CGENCompugen-$0.07N/AN/AN/A$3.95 millionN/A5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACDAKCodiak BioSciencesN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/APSTXPoseida TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A9.249.02CDAKCodiak BioSciences0.664.244.24CGENCompugenN/A5.095.09OYSTOyster Point Pharma8.493.353.11PSTXPoseida Therapeutics0.683.203.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CDAKCodiak BioSciences71.30%CGENCompugen12.22%OYSTOyster Point Pharma96.70%PSTXPoseida Therapeutics46.87%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CDAKCodiak BioSciences8.20%CGENCompugen9.50%OYSTOyster Point Pharma17.90%PSTXPoseida Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCDAKCodiak BioSciences10236.83 million33.81 millionNot OptionableCGENCompugen7089.24 million80.76 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionablePSTXPoseida Therapeutics26097.77 million94.94 millionOptionableCGEN, AUTL, CDAK, PSTX, and OYST HeadlinesRecent News About These CompaniesRoche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/WinJanuary 9, 2025 | seekingalpha.comRoche set to finalise $1.5bn Poseida Therapeutics takeoverJanuary 8, 2025 | proactiveinvestors.comRoche to complete acquisition of U.S. biopharma company PoseidaJanuary 8, 2025 | reuters.comWhat Factors Have Led to Poseida Therapeutics Inc (PSTX) Stock Trading -0.93% Below Its 52-Week High?January 7, 2025 | bovnews.comBPoseida Therapeutics Inc (PSTX) Stock Rated Neutral by Piper SandlerJanuary 4, 2025 | bovnews.comBPoseida Therapeutics Inc (PSTX) Stock: More Resilient Than It AppearsJanuary 4, 2025 | bovnews.comBPoseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?December 13, 2024 | zacks.comMark J. Gergen Sells 30,000 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) StockDecember 12, 2024 | insidertrades.comCautious Hold Rating on Poseida Therapeutics Amid Promising Data and Strategic UncertaintiesDecember 10, 2024 | markets.businessinsider.comPoseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | prnewswire.comPoseida Therapeutics downgraded to Neutral from Overweight at Piper SandlerDecember 2, 2024 | markets.businessinsider.comThe PSTX Stock Mystery: Why Did PSTX Plunge Today?December 2, 2024 | bovnews.comBRoche’s Acquisition Offer Leads to Hold Rating for Poseida Therapeutics Amid Promising Pipeline and Financial UncertaintiesDecember 2, 2024 | markets.businessinsider.comThe Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and NovartisDecember 2, 2024 | uk.finance.yahoo.comPoseida Therapeutics Inc (PSTX) Stock: Beyond the Surface of Its Performance?November 29, 2024 | bovnews.comBShould You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?November 28, 2024 | zacks.comPoseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Sells $278,100.00 in StockNovember 28, 2024 | insidertrades.comPOSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida ...November 28, 2024 | businesswire.comPOSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTXNovember 27, 2024 | businesswire.comWhat’s Fueling Poseida Therapeutics Inc (PSTX) Stock’s 214.65% Gain Above Its 200-Day SMA?November 27, 2024 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGEN, AUTL, CDAK, PSTX, and OYST Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$2.47 -0.01 (-0.40%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.49 +0.02 (+0.81%) As of 07/11/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Codiak BioSciences NASDAQ:CDAKCodiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Compugen NASDAQ:CGEN$1.59 -0.10 (-5.92%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 07/11/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Poseida Therapeutics NASDAQ:PSTXPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Conagra at Rock Bottom: 7% Yield & Turnaround Poised Delta Air Lines Could Reach New Highs in 2025—And Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
